Comorbid IBS Affects PPI Treatment for GERD

Published Online: Sunday, August 1, 2004

Patients with irritable bowel syndrome (IBS) frequently suffer from symptoms that are characteristic of gastroesophageal reflux disease (GERD), suggesting that comorbidity is not uncommon. It is not known, however, whether comorbid IBS in patients with GERD affects the efficacy of proton pump inhibitors (PPIs), which are typically used to treat patients with GERD.

A study conducted by William D. Chey, MD, and colleagues, presented at the 105th Annual Meeting of the American Gastroenterological Association and Digestive Disease Week (DDW), held from May 15 to 20, 2004, in New Orleans, La, examined the relationship between the presence of comorbid IBS and PPI efficacy in patients with GERD (n = 68). Results showed that patients with GERD and comorbid IBS have more severe GERD symptoms than do individuals with GERD alone. Also, patients with both GERD and IBS are more likely to experience residual GERD symptoms during PPI therapy than are those with GERD alone.

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues